Squarepoint
PTGX icon

Squarepoint’s Protagonist Therapeutics PTGX Stock Holding History

Squarepoint’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,566
Closed -$835K – 5409
2024
Q3 		$835K Buy
18,566
+8,743
+89% +$353K ﹤0.01% 2741
2024
Q2 		$340K Buy
+9,823
New +$288K ﹤0.01% 3347
2023
Q1 		– Sell
-21,770
Closed -$238K – 3695
2022
Q4 		$238K Sell
21,770
-55,092
-72% -$465K ﹤0.01% 2698
2022
Q3 		$648K Buy
76,862
+22,186
+41% +$210K ﹤0.01% 2068
2022
Q2 		$432K Buy
54,676
+40,866
+296% +$494K ﹤0.01% 2091
2022
Q1 		$327K Sell
13,810
-46,680
-77% -$1.32M ﹤0.01% 2235
2021
Q4 		$2.07M Buy
+60,490
New +$1.91M 0.01% 1237
2021
Q1 		– Sell
-16,893
Closed -$341K – 3516
2020
Q4 		$341K Buy
+16,893
New +$364K ﹤0.01% 2115
2020
Q3 		– Sell
-118,120
Closed -$3.41M – 2776
2020
Q2 		$3.41M Buy
118,120
+81,037
+219% +$1.02M 0.06% 461
2020
Q1 		$262K Sell
37,083
-56,020
-60% -$420K 0.01% 1360
2019
Q4 		$656K Buy
93,103
+9,069
+11% +$90.1K ﹤0.01% 1602
2019
Q3 		$1.01M Sell
84,034
-18,303
-18% -$231K 0.01% 1231
2019
Q2 		$1.24M Buy
102,337
+57,560
+129% +$636K 0.01% 1131
2019
Q1 		$563K Buy
44,777
+18,973
+74% +$167K 0.01% 1422
2018
Q4 		$174K Sell
25,804
-10,306
-29% -$81.7K ﹤0.01% 1725
2018
Q3 		$372K Sell
36,110
-12,357
-25% -$106K ﹤0.01% 1444
2018
Q2 		$326K Buy
48,467
+31,936
+193% +$245K ﹤0.01% 1347
2018
Q1 		$142K Buy
+16,531
New +$311K ﹤0.01% 1542

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's PTGX Position: Q4 2024 in Review

Squarepoint sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 18,566 shares — an estimated $835K sold.

Squarepoint first reported a position in PTGX in Q1 2018 and held it in 18 quarters. The position peaked at $3.41M in Q2 2020. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Squarepoint reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Squarepoint sold 18,566 Protagonist Therapeutics shares in Q4 2024, an estimated $835K.
  • Squarepoint first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 18 quarters.
  • Squarepoint's Protagonist Therapeutics position peaked at $3.41M in Q2 2020.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.